Prostic Preceptorship 2022, happening the 1st and 2nd of April

Committee

Dr. James Buteau

Dr Buteau completed his medical training in Canada with a specialization in nuclear medicine at the University of Sherbrooke. Following two years of practice among the dynamic team at Hôpital de la Cité-de-la-Santé, he undertook a 12-month fellowship in Theranostics at Peter Mac. In 2020, he was awarded with the Detweiler Travelling Fellowship by the Royal College of Physicians and Surgeons of Canada.

Prof. Michael Hofman

Professor Michael Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in oncology. This includes neuroendocrine tumours and haematologic applications and more recently he has focussed on improving outcomes for men with prostate cancer.

Michelle McDade

Michelle McDade is an experienced health service executive having held operational roles in both the public and private health care sector. Michelle’s career is highlighted by her approach to quality and innovation, with successful submission for a number of grants through the Victorian Department of Business and Innovation. Michelle completed the Department of Health LINK Leadership program in 2011, and travelled internationally in 2010 through a Victorian Quality Council Travelling Fellowship, studying excellence in Emergency Departments. Michelle has previously worked as a Physiotherapist, and holds a Masters of Business Administration.

Elizabeth Medhurst

Elizabeth Medhurst has been a Genitourinary nurse consultant for the past four years. Elizabeth has developed a keen interest in metastatic prostate cancer and is passionate about participating in prostate cancer research and highlighting the importance of the nursing role throughout the process. 

Prof. Declan Murphy

Professor Declan Murphy is Consultant Urologist and Director of Genito-Urinary (GU) Oncology at Peter MacCallum Cancer Centre, Melbourne, and Professorial Fellow at the University of Melbourne. He is a founding Director of Cancer Specialists.

Annette Van Der Heyden
Annette Van Der Heyden

Annette Van Der Heyden brings to ProsTIC over 17 years’ experience in clinical and medical research administration.  As a Professional Conference Organiser, her experience and success facilitating and coordinating some of Australia’s pre-eminent local and international medical research meetings, has resulted in a reputation for exceptional project delivery, commitment and excellence. 

A/Prof. Arun Azad

Medical Oncologist

Associate Professor Arun Azad is an internationally recognised medical oncologist and translational researcher in urological cancers, with a particular focus on prostate cancer.

 

After completing his medical training and a PhD at Peter Mac, he undertook a Fellowship in a world-renowned prostate cancer clinical and research program in Vancouver, under the supervision of Professor Kim Chi.

A/Prof. Himisha Beltram

Medical Oncologist

Dr. Beltran is an Associate Professor of Medicine in the Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology. She is also the Director of Translational Research within Medical Oncology.

A/Prof. Jeremie Calais

Nuclear Medicine Physician

Dr. Jeremie Calais is Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. He is also a member of the Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches.

Dr. Renu Eapen

Urologist

Dr Renu Eapen is a Consultant Urologist in the Genitourinary Oncology service at the Peter MacCallum Cancer Centre. She also has appointments at the Austin Hospital and Olivia Newton-John Cancer Centre.

Barry and Lorraine Elderfield
Lorraine Elderfield

Consumer Advocates

Barry, a retired industrial chemist/chemical engineer, and his wife Lorraine take a keen interest in the study of new and developmental prostate cancer treatments - particularly those which are likely to be helpful for Barry’s own ongoing treatment. For years now they have spent much of their time as patient/consumer advocates providing support for prostate cancer patients and their families. Together Barry & Lorraine work tirelessly to support PCa patients and their partners

Prof. Louise Emmett

Nuclear Medicine Physician

Prof. Louise Emmett is Nuclear medicine physician with a specialty interest in the PET imaging and therapy of prostate Cancer. She undertook her medical undergraduate training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney, and a post specialty fellowship in Toronto, Canada in 2001.

A/Prof. Roslyn Francis

Nuclear Medicine Physician

A/Prof Roslyn Francis is an academic Nuclear Medicine Physician. She is Head of Department at Sir Charles Gairdner Hospital Nuclear Medicine/WA PET Service and holds an academic role as Associate Professor of Molecular Imaging with University of Western Australia. Her research interests are focused on the role of imaging in clinical trials, quantitative imaging/analytics and investigating novel PET tracers.

Allen Hart

Consumer Advocate

Allen Hart is a father of three adult sons and the owner/operator of a small financial planning business. In August 2020, following routine blood work, Allen was shocked to learn he had an aggressive prostrate cancer that had spread to surrounding lymph nodes. Searching for the best outcome possible, Dr. Declan Murphy introduced Allen to a clinical trial he was leading. Allen responded very well to the treatment and has been living cancer free since. Being a consumer advocate is one way Allen can hopefully give something back to Peter Mac and assist where required.

Prof. Michael Hofman

Nuclear Medicine Physician

Professor Michael Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne.

 

He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in oncology. This includes neuroendocrine tumours and haematologic applications and more recently he has focussed on improving outcomes for men with prostate cancer.

A/Prof. Grace Kong

Nuclear Medicine Physician

Grace Kong is a Nuclear Medicine Physician at the Peter MacCallum Cancer Centre (PMCC) in Melbourne Australia, a Clinical Associate Professor at the University of Melbourne, Sir Peter MacCallum Department of Oncology. She previously completed a PET and radionuclide therapy fellowship at the Royal Marsden Hospital, UK. She has clinical leadership roles as the Radionuclide Therapy Modality Lead of Cancer Imaging, Chair of the weekly Radionuclide Therapy Neuroendocrine Tumour (NET) multidisciplinary meeting (MDM), the Nuclear Medicine Lead for the Upper Gastrointestinal tumor stream MDM and a committee member of the PMCC ENETS Centre of Excellence.

Prof. Klaus Kopka

Radiopharmaceutical Chemist

Prof. Dr. Klaus Kopka (HZDR) is radiopharmaceutical chemist and holds a full professorship (W3) for Bioinorganic and Radiopharmaceutical Chemistry at TU Dresden, Germany, which is combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR].

Dr. Aravind Ravi Kumar

Nuclear Medicine Physician

Dr. Aravind S. Ravi Kumar is a nuclear medicine physician at the Peter MacCallum Cancer Centre. Aravind was awarded his medical degree from Sydney University in 1995 and his FRACP in Nuclear Medicine in 2003 via a detour in clinical haematology. He worked at the Royal Brisbane and Women’s Hospital for 12 years before moving to the Peter MacCallum Cancer Centre in 2016. He is an active member of multi-disciplinary teams and has a strong interest in theranostics and enjoys opportunities for integrating clinical and technical aspects of practice. He is currently involved in clinical care and research in prostate, neuroendocrine and thyroid cancers, and has had multiple other roles in governance, education and training from local to national levels throughout his career.

Dr. Andrea Miyahira (PCF)

Director, Global Research & Scientific Communications

Andrea Miyahira is a Ph.D. scientist, science communicator & program administrator with 15+ years of biomedical research experience and in depth-knowledge in oncology, cancer-immunology, immunology, and clinical studies.

Prof. Declan Murphy

Urologist

Professor Declan Murphy is Consultant Urologist and Director of Genito-Urinary (GU) Oncology at Peter MacCallum Cancer Centre, Melbourne, and Professorial Fellow at the University of Melbourne. He is a founding Director of Cancer Specialists.

A/Prof. Shahneen Sandhu

Medical Oncologist

A/Professor Sandhu is a Medical Oncologist and an early-career researcher and with a full time appointment in uro-oncology and melanoma units at the Peter MacCallum Centre, Melbourne. She trained at the Royal Marsden NHS Foundation Trusts/Institute of Cancer Research Drug Development Unit, and was responsible for designing, implementing and supervising early phase adaptive, biomarker driven trials. Over the course of her research career, A/Professor Sandhu has made important original contributions to cancer research, particularly in the development and application of clinical biomarkers. She continues to undertake clinical and translational research in immune-oncology in melanoma and prostate cancer with a focus on using imaging and circulating biomarkers to molecularly stratify treatment.

A/Prof. Shankar Siva

Radiation Oncologist

Associate Professor Shankar Siva is a Radiation Oncologist and current Cancer Council Victoria (CCV) Colebatch Fellow. He leads the Stereotactic Ablative Body Radiotherapy (SABR) program at the Peter Mac and is internationally recognised for his work in high technology radiotherapy delivery. He completed his PhD with the Molecular Radiation Biology (Martin) Laboratory focusing on translational investigations in precision high-dose lung radiotherapy. He published the first original research from Australia on the use of the SABR technique.

Prof. Scott Williams

Radiation Oncologist

Professor Scott Williams is a radiation oncologist who works exclusively with urological cancers, and in particular, prostate cancer. He is Professor of Oncology at University of Melbourne and Honorary Professor of Medicine at University of Queensland. Scott has an international profile as the lead of several large global studies of hormonal therapy combined with radiotherapy in prostate cancer, while also managing multiple smaller studies locally and nationally. His research largely focuses on how prostate cancer responds to radiation therapy (in particular related to brachytherapy), including recent molecular and immune system insights derived from extensive laboratory investigations

Prof. Felix Feng

Radiation Oncologist
USA

Felix Feng, MD, received his undergraduate training from Stanford University, where he earned a degree in Biological Sciences and received a President’s Award for Academic Excellence. He then received his MD from Washington University in St. Louis, where he received numerous awards for his research and academic achievements. 

Kirsten Greene

Urologist